Whanin Pharm Co Ltd
KRX:016580
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (4.4), the stock would be worth ₩7 897.1 (27% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.1 | ₩10 780 |
0%
|
| 3-Year Average | 4.4 | ₩7 897.1 |
-27%
|
| 5-Year Average | 4.7 | ₩8 275.62 |
-23%
|
| Industry Average | 16.8 | ₩29 904.05 |
+177%
|
| Country Average | 8.5 | ₩15 169.81 |
+41%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
₩126.7B
|
/ |
Jan 2026
₩22.4B
|
= |
|
|
₩126.7B
|
/ |
Dec 2026
₩27.9B
|
= |
|
|
₩126.7B
|
/ |
Dec 2027
₩31.3B
|
= |
|
|
₩126.7B
|
/ |
Dec 2028
₩34.7B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
W
|
Whanin Pharm Co Ltd
KRX:016580
|
199.3B KRW | 6.1 | 14.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 28.5 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.6 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 16.2 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 9.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 7.6 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.4B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.3 |
| Median | 8.5 |
| 70th Percentile | 15.6 |
| Max | 24 013.5 |
Other Multiples
Whanin Pharm Co Ltd
Glance View
Whan In Pharmaceutical Co., Ltd. engages in the manufacture and sale of medical supplies. The company is headquartered in Seoul, Seoul. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Company’s products consist of antidepressants, antipsychotics, anxiolytics, hypnotics, antiepileptics, attention-deficit/hyperactivity disorder (ADHD) agents, nootropics, antiparkinson drugs, anti-dementia drugs, gastrointestinal drugs, cardiovascular drugs, immunostimulating agents, antibiotics, multi-vitamins, respiratory drugs, dermatologic drugs, antivirals, anti-diabetic agents and others. The firm also involves in the real estate rental business.
